Arbutus Biopharma Corporation (ABUS)
Nasdaq: ABUS · Pharmaceutical Preparations · Warminster, PA · filing with the SEC since 2008
Who owns Arbutus Biopharma Corporation
As filed with the SECHolders of 5% or more
5
Roivant Sciences Ltd. holds 19.5% of Common Shares, without par value, as its SCHEDULE 13D/A filed Oct 5, 2026 says.
Directors and officers
5
report now, of 39 people on the record since 2014. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Roivant Sciences Ltd.
SCHEDULE 13D/A · filed Oct 5, 2026 · Common Shares, without par value · 20.5% in Feb 25, 2025
Morgan Stanley
SCHEDULE 13G/A · filed Oct 7, 2026 · Common Shares · 8.8% in Aug 12, 2026
Two Seas Capital LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Shares, without par value · 6.5% in Feb 17, 2026
Whitefort Capital Master Fund, LP
SCHEDULE 13G · filed Sep 4, 2026 · Common Shares, without par value · 8% in Apr 28, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock
What ABUS reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Enantigen
A company bought · acquisition · owns, named in the 10-K filed Mar 23, 2026
Enantigen's Selling Shareholders
A company bought · acquisition · owns, named in the 10-K filed Mar 23, 2026
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 23, 2026.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 7, 2025 to Oct 7, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Oct 7, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.